The drug resistance of tyrosine kinase inhibitors (TKIs) becomes a critical challenge for the treatment of CML29, it is thus urgent to find novel anti-CML drugs by targeting BCR-ABL. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.